KOLMAR BNH Co.,Ltd. (KOSDAQ:200130)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,580
-70 (-0.48%)
Aug 8, 2025, 3:30 PM KST
-0.48%
Market Cap412.54B
Revenue (ttm)592.15B
Net Income (ttm)12.67B
Shares Out28.29M
EPS (ttm)437.57
PE Ratio33.32
Forward PEn/a
Dividend308.00 (2.10%)
Ex-Dividend DateMar 26, 2025
Volume24,273
Average Volume43,610
Open14,600
Previous Close14,650
Day's Range14,520 - 14,780
52-Week Range11,030 - 16,370
Beta0.49
RSI49.48
Earnings DateAug 14, 2025

About MorphoSys AG

Kolmar BNH Co., Ltd. engages in the research and development of materials used in the functional health food and cosmetics market in South Korea and internationally. The company offers cosmetics; and provides total functional health food original development manufacturing services, such as manufacturing tablets, hard capsules, soft capsules, liquids, gels, powder dosage, and various new formulation forms. It offers packaging products, such as PTP/multi-PTP, powder stick/pouch, three-side cloth, four-side, and liquid stick packaging; and ODM con... [Read more]

Founded 2004
Employees 521
Stock Exchange KOSDAQ
Ticker Symbol 200130
Full Company Profile

Financial Performance

In 2024, KOLMAR BNH's revenue was 615.64 billion, an increase of 6.23% compared to the previous year's 579.55 billion. Earnings were 18.05 billion, a decrease of -8.41%.

Financial Statements

News

Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement

SEOUL, South Korea — Kolmar BNH (KRX: 200130), a leading Korean health functional food Original Development Manufacturing (ODM) firm, is at the forefront of Environmental, Social, and Governance (ESG)...

9 months ago - Financial Post

HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA

SEOUL, South Korea — ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration...

10 months ago - Financial Post